1. Buprenorphine/naloxone access for people with opioid use disorder in correctional facilities: taking steps to support knowledge translation
- Author
-
Lori Regenstreif, Marina Sadik, Erin Beaulieu, Claire Bodkin, Lori Kiefer, Dale Guenter, Patsy W. P. Lee, and Fiona G. Kouyoumdjian
- Subjects
Opioid use disorder ,Opioid agonist treatment ,Buprenorphine ,Correctional facility ,Prison ,Jail ,Public aspects of medicine ,RA1-1270 ,Social pathology. Social and public welfare. Criminology ,HV1-9960 - Abstract
Abstract People with opioid use disorders are overrepresented in correctional facilities, and are at high risk of opioid overdose. Despite the fact that buprenorphine/naloxone is the first line treatment for people with opioid use disorder, there are often institutional, clinical, and logistical barriers to buprenorphine/naloxone initiation in correctional facilities. Guided by the knowledge-to-action framework, this knowledge translation project focused on synthesizing knowledge and developing a tool for buprenorphine/naloxone initiation that was tailored to correctional facilities, including jails. This information and tool can be used to support buprenorphine/naloxone access for people in correctional facilities, in parallel with other efforts to address barriers to treatment initiation in correctional facilities.
- Published
- 2022
- Full Text
- View/download PDF